FunPep Resultados de beneficios anteriores
Pasado controles de criterios 0/6
FunPep has been growing earnings at an average annual rate of 31%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been declining at an average rate of 100% per year.
Información clave
31.0%
Tasa de crecimiento de los beneficios
41.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 31.9% |
| Tasa de crecimiento de los ingresos | -100.0% |
| Rentabilidad financiera | -33.9% |
| Margen neto | n/a |
| Próxima actualización de resultados | 14 Nov 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero FunPep. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -727 | 265 | 455 |
| 31 Mar 24 | 0 | -760 | 267 | 484 |
| 31 Dec 23 | 0 | -933 | 267 | 680 |
| 31 Dec 22 | 1 | -1,172 | 222 | 912 |
Ingresos de calidad: 4881 is currently unprofitable.
Margen de beneficios creciente: 4881 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Unable to establish if 4881's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Acelerando crecimiento: Unable to compare 4881's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 4881 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Rentabilidad financiera
Alta ROE: 4881 has a negative Return on Equity (-33.88%), as it is currently unprofitable.